cyrilzakka/clinical-trials huggingface dataset:
Effects of Whole-body Electrostimulation on Patients With Chronic Kidney Disease

Chronic kidney disease (CKD) consists of kidney damage, with consequent progressive and irreversible loss of kidney function. In the early stages of the disease, a reduction in circulating levels of the α-klotho protein is already observed, which is related to worsening renal function. Therapeutic strategies that increase serum levels of α-klotho may be of great value in the treatment of CKD. Electrical stimulation contributes to the reduction of reactive oxygen species, DNA damage and improves the effectiveness rate of dialysis, suggesting a systemic effect in patients with terminal CKD. The objective of this study is to evaluate the effects of whole body electrical stimulation on renal function and physical capacity in patients with CKD not dependent on dialysis.

Patients with stage III and IV chronic kidney disease will be randomized into two groups, one group will receive whole-body electrical stimulation and the other group will be a control group (it will only be evaluated and reevaluated at the same times as the intervention group). The intervention group will perform the protocol three times a week, for eight weeks. The following assessments will be conducted pre- and post-intervention: analysis of plasma content of soluble α-Klotho and creatinine to assess renal function; measurement of interleukins and tumor necrosis factor by ELISA to analyze the inflammatory profile; beta-endorphin measurement by ELISA to assess well-being; creatine kinase dosage to assess muscle damage; 10-repetition sit-to-stand test and quadriceps muscle dynamometry to assess lower limb muscle strength; handgrip test with a dynamometer to assess upper limb strength; six-minute walk test to assess functional capacity; application of the EuroQoL-5D questionnaire for quality of life and the Pittsburgh scale to assess sleep quality.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with CKD (≥ 3 months) in stages 3-4 (GFR between 59 and 15 ml/min/1.73m2);
* Age between 18 and 80 years old;
* Functional capacity ≥ 300 meters in the six-minute walk test.

Exclusion Criteria:

* Cognitive dysfunction that prevents assessments from being carried out or inability to understand and sign the informed consent form;
* Intolerance to electrical stimulator and/or changes in skin sensitivity;
* Skin injuries or burns where the electrodes are positioned;
* Patients with stroke sequelae;
* Recent acute myocardial infarction (two months);
* Uncontrolled hypertension (SBP\>230 mmHg and DBP\>120 mmHg);
* New York Heart Association grade IV heart failure or decompensated;
* Unstable angina or arrhythmia;
* Artificial cardiac pacemaker or implantable cardioverter defibrillator;
* Peripheral vascular changes in the lower limbs such as deep vein thrombosis;
* Disabling osteoarticular or musculoskeletal disease;
* Uncontrolled diabetes (glycemia \> 300mg/dL);
* Patients with cancer and/or undergoing oncological treatment;
* Epilepsy;
* Hemophilia;
* Chronic obstructive pulmonary disease;
* Grade II obesity (BMI≥35).
Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya

To investigate the use of self-administered artesunate vaginal pessaries as treatment for cervical precancer in low and middle-income countries (LMIC). The central hypothesis of this study is that self-administered intravaginal Artesunate will be safe, and result in a clinical response among both HIV-positive and HIV-negative women with cervical precancer in LMICs.

Despite being preventable, cancer of the cervix is a leading cause of cancer death in Kenya and other low- and middle-income countries (LMIC). Cervical cancer can be prevented if early changes in the cervix, called cervical precancer, are detected through screening, and adequately treated. Cervical precancer treatment includes a surgical procedure called Loop Electrosurgical Excision Procedure (LEEP), which removed the involved area of the cervix.

In countries like Kenya, this LEEP procedure is only available in referral hospitals which have trained consultants, and hence is difficult to access for most women who live in rural areas and away from tertiary facilities. Additionally, the LEEP procedure also increases the chance of a woman not being able to carry a pregnancy to full term, because the cervix is shorter after the procedure. For these reasons, alternative treatments, including self-administered treatments such as Artesunate are being investigated as alternative cervical precancer treatment that can be self-administered.

Eligibility Criteria:
Inclusion Criteria:

1. Cervical lesions referred for excision with CIN2/3 diagnosis on biopsy
2. Weight ≥50 kg
3. Agreement to use contraception (barriers or hormonal) through week 24 of the study if of childbearing age.
4. Ability and willingness to provide informed consent.

Exclusion Criteria:

1. Current pregnancy or breastfeeding status.
2. Current or past history of invasive cervical cancer.
3. History of total hysterectomy.
4. CD4 count less than 200 cells/mm3.
5. Presence of adenocarcinoma in situ on cervical biopsy
6. Currently receiving systemic chemotherapy or radiation therapy for another cancer
7. Current use of systemic immunosuppressants or steroids (\>10 mg of prednisone or equivalent)
8. Have a medical comorbidity that in the opinion of the investigator would interfere with study participation.
9. Prior chemotherapy within 1 month prior to day 1 of study treatment
10. Male at birth
Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials

We aimed to compare efficacy and safety of combination therapy with oral ofloxacin, 400 mg twice daily, plus oral metronidazole, 500 mg twice daily, for 14 days, with moxifloxacin monotherapy, 400 mg once daily, for 14 days


Eligibility Criteria:
Inclusion Criteria:

1. Women diagnosed uncomplicated PID
2. Patients age are between 14 with 45
3. Pelvic tenderness and vaginal discharge

Exclusion Criteria:

1. Urinary Tract Enfections
2. Tubo-ovarian abscess and complicated PID
3. Hıstory of antibiotics treatment
4. Other pelvic pain causes
5. Endometriosis
6. Delivery,abortion and surgery within last months
Repetitive Transcranial Magnetic Stimulation for Lower Limb Spasticity in Multiple Sclerosis Patients

Leg spasticity is common problem encountered with a large proportion of patients suffering with multiple sclerosis (MS) with an increasing severity as the disease progresses. It mostly affects the antigravity muscles that significantly complicates transfer, increases fatigue and makes walking more difficult. Hence, leg spasticity often interferes with patients' mobility and significantly influences their quality of life. A great number of multidisciplinary rehabilitation studies has shown a significant effect of numerous specific functional changes in patients with secondary (SP) and primary progressive (PP) MS but there are no reviews related to spasticity. The positive therapeutic effect of modulating Transcranial Magnetic Stimulation ( TMS) methods on spasticity is shown in only two studies, in patients with relapse remitting clinical form in the remission phase of the disease. The effect of TMS on clinical measures of lower limb spasticity, functional inability and the quality of life in patients with SPMS and PPMS will be examined in this study. The objective to this study are to to explore whether rTMS boosted exercise therapy (ET) treatment can bring more improvement in lower limb spasticity than ET treatment alone in these patients.


Eligibility Criteria:
Inclusion Criteria:

* Confirmed clinical form of SPMS and PPMS (established on the basis of the revised McDonald criteria)
* EDDS score 2-6.5
* lower limb spasticity caused by MS
* 18 years ≥age of the patient ≤ 65. years

Exclusion Criteria:

* clinical worsening of the disease over the past 30 days,
* the presence of pregnancy, dementia, alcoholism, history of loss of consciousness, epilepsy, metal objects in the head, pacemakers and other electronic devices in the body at a distance of 20cm from the top of the patients head, serious associate diseases (malignancy, heart disease).
Gut Transit Effect on Enterohepatic Circulation

A study to determine the influence of changing intestinal transit time of the enterohepatic recirculation of bile acids.

The digestion of food by human body starts from oral cavity and continues until its excreted as faeces. There are different factors affecting this process. Important factors are movement through the GI Tract, breakdown of food material and absorption by the body to produce energy. The unabsorbed waste material is then excreted by the body.

Different enzymes are produced by human body which are responsible for digestion of food. One important chemical is bile which is produced in the gall bladder. It is important in digestion of fatty foods but affects the movement of food material as well. There are numerous bacteria present in human GI tract especially in mouth and large bowel which also play an important role in process of digestion of food.

Different conditions of health and disease can affect how food moves through the GI tract (known as intestinal transit). It also affects the activity of different digestive enzymes and chemicals in body. The bacterial population in the body is also affected by changes described above. The purpose of this study is to observe how these different processes especially the intestinal transit, bile salts and gut bacteria affect each other. This will help to identify mechanisms responsible for different disorders of human gut like irritable bowel syndrome. The study is part of an effort to identify new and future treatment of these conditions.

Eligibility Criteria:
Inclusion Criteria:

* • Healthy volunteers between the ages of 18 and 65

Exclusion Criteria:

* Unable to consent
* Pregnant or lactating
* Known diarrhoeal disorder
* Known constipation.
* Any gastrointestinal disease or previous gastric surgery
* An episode of gastroenteritis within the last month
* Taking any acid suppressing medication
* Any significant medical condition (e.g. diabetes, renal disease)
* Any antibiotic intake within the last one-month
* Any drug with known effects on GI motility
* Known allergy or intolerance to senna or loperamide
Awareness, Care & Treatment In Obesity Management

ACTION France is a cross-sectional, observational, descriptive, and exploratory survey-based study without collection of laboratory data. The study is not related to any specific treatment options or pharmaceutical product. Collection of data will be performed via quantitative online survey by a third-party vendor.

The goal of this study is to provide insights to drive awareness around the needs of People Living with Obesity (PLwO) and Health Care Professionals (HCPs) involved in obesity treatment and management.


Eligibility Criteria:
Inclusion Criteria:

People Living with Obesity

1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
2. Male or female, aged above or equal to 18 years at the time of signing informed consent Lives in France
3. Current BMI based on self-reported height and weight of at least 30 kg/m\^2

Health Care Professionals

1. Informed consent before any study related activities (study-related activities are any procedure related to recording/collection of data according to protocol)
2. Male or female, aged greater than or equal to 18 years at the time of signing informed consent.
3. Physician with a license to practice
4. Specialty is not surgeon (including bariatric or plastic surgeon)
5. Practices in France
6. In clinical practice greater than or equal to 2 years
7. Spends at least 70 percent time in direct patient care
8. Has seen at least 100 patients in past month
9. Has seen at least 10 patients in past month needing weight management defined as: a patient with a BMI greater than or equal to 30 kg/m\^2 with or without comorbidities.

Employers

1. Informed consent before any study related activities (study-related activities are any procedure related to recording/collection of data according to protocol)
2. Age 18 years old or older
3. works in France
4. Company offers health insurance benefits
5. Responsible for making or influencing decisions about employee benefits plan or health and wellness programs
6. works in a company that has at least 20 employees
7. not affiliated with pharma, MR or advertising firms

Exclusion Criteria:

People Living with obesity

1. Previous participation in this study. Participation is defined as having given online consent in this study
2. Currently pregnant
3. Participates in intense fitness or body building programs
4. Has had significant, unintentional weight loss (due to major injury, illness, etc) in the past 6 months
5. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Health Care Providers

1. Previous participation in this study. Participation is defined as having given informed consent in this study.
2. Unwillingness, inability, or language barriers precluding adequate understanding or cooperation.

Employers

1. Previous participation in this study. Participation is defined as having given informed consent in this study.
2. Unwillingness, inability, or language barriers precluding adequate understanding or cooperation.
Evaluating the Safety and Efficacy of a Outpatient Appendectomy

This study evaluates the Safety and Efficacy of a outpatient appendectomy. Half of participants will be perform the hospitalization, while the other half will undergo the outpatient appendectomy

Acute appendicitis (AA) is one of the most common causes of acute abdomen and one of the most frequent diagnoses that require urgent surgery worldwide.

Many laparoscopic procedures are currently performed on an outpatient basis.Laparoscopic appendectomy, however, continues to require postoperative hospitalization averaging between 1 and 2 days, at most institutions.

At present ambulatory laparoscopic appendectomy (LA) are gained popularity due to the improved understanding of patient selection criteria, the application of enhanced recovery pathways, and the potential for improving healthcare resource utilization.

There are few studies about to compare the morbidity and readmission rates between ambulatory and conventional LA.

There is a lack of high-quality comparative studies making conclusive recommendations not possible at this time. Based on current data, ambulatory LA may be safe and feasible as compared with conventional LA.

Eligibility Criteria:
Inclusion Criteria:

* Patients over 14 years of age and who provide informed consent to participate in the study.
* Patients with non complicated acute appendicitis requiring and urgent appendectomy (laparoscopic or minimum incision)
* Negative appendicectomy.

Exclusion Criteria:

* Complicated acute appendicitis (abscess, perforated, necrosis and peritonitis)
* Need to place intraoperative drainage.
* Patients with American Society of Anesthesiologists (ASA) \>IV.
* Immunosuppressed patients.
* Pregnant.
* Possibility of inflammatory bowel disease.
* No family support.
* No informed consent signature.
* Impossibility to comply with the established follow-up
Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8

The purpose of this study is to examine two medications, modafinil and citalopram, in the treatment of cocaine dependent individuals who are maintained on methadone.

This is a 24-week, randomized, double-blind, placebo-controlled study examining two doses of modafinil (200 and 400 mg) and citalopram (20 and 40 mg) in the treatment of methadone maintained cocaine dependent individuals.

Participants will first be given methadone to determine its tolerated and effective doses. Most participants will be able to reach a stable dose of methadone within 7 to 10 days of methadone initiation. When 80% of the projected dose of methadone has been achieved, participants will begin the medication regimen of modafinil or citalopram. Modafinil will be given over a 7-day period. Dosing of modafinil will begin at 200 mg and, depending on the individual, may increase to 400 mg. Citalopram will be given in increasing doses, starting at 20 mg and increasing to 40mg.

Eligibility Criteria:
Inclusion Criteria:

* Meets cocaine abuse and dependence criteria (as determined by the SCID)
* Meets opiate dependence criteria (as determined by the SCID)
* In good general physical and psychiatric health (except for possible acute drug use related problems)

Exclusion Criteria:

* Meets diagnostic criteria for other psychiatric disorders, including other forms of drug dependence (other than nicotine)
* Current cardiovascular disease (as determined by an electrocardiogram)
* Circumstances will not allow for completion of study (on probation or parole)
* Ethical constraints of supervision do not allow confidentiality (on probation or parole)
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.


Eligibility Criteria:
Inclusion Criteria:

* Patients who have received at least one dose of a Juno CAR T-cell product (listed above) in a Juno-sponsored clinical trial
* Patients who have provided informed consent for the long-term follow-up study

Exclusion Criteria:

* None. All patients who have previously received treatment with a Juno CAR T-cell product are eligible for this long-term follow-up study.
Evaluation of Ultra-portable Ultrasound in General Practice

This is an interventional multi-centre study comparing two groups of general practitioners with or without an ultrasound scanner over a period of 6 months. The evaluation focuses on the management of patients for 8 pathologies:

* Pneumonia
* Pleural effusion
* Renal colic
* Hepatic colic or cholecystitis
* Subcutaneous abscess or cyst
* Fracture of long bones
* Intra-uterine pregnancy or extra-uterine pregnancy or miscarriage
* Phlebitis The principal hypothesis is that there are fewer complementary exams in the group of doctors using ultrasound scanners.

The secondary hypotheses are:

* There is better patient orientation (emergency care, specialist consultation, return home) in the group of doctors using the ultrasound scanners.
* The global cost of the care is lower in the group of doctors using the ultrasound.
* Using ultrasound during the consultation decreases the anxiety of the patient.
* Using ultrasound increases the duration of the consultation.
* There is no difference between the predicted and the real orientation of the patients.


Eligibility Criteria:
Inclusion Criteria:

* patients age 18 and over
* consulting their general practitioner for one of the 8 conditions below

Exclusion Criteria:

* patients who have already received an imagery exam for the acute episode justifying the consult
* opposition to participate
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

This is a non-interventional, multi-center, ambispective cohort study in real world to describe the effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.

This is a multi-center observational study with both retrospective and prospective data collections to describe the effectiveness and safety of sequential dacomitinib and 3rd generation EGFR-TKI used in patients with EGFR mutation-positive NSCLC with T790M-aquired resistance in a clinical practice setting. The study will include patients who were or will be diagnosed as advanced NSCLC with EGFR mutation positive and received dacomitinib as first-line treatment followed by second-line 3rd generation EGFR-TKI treatment in multiple tertiary care hospitals after Sep 1st, 2019. Patients' clinical information prior to the study initiation in each hospital will be collected retrospectively through chart review. After the study initiation, new patient enrollment will last till Dec 2022. Patients' clinical care after the study initiation will be followed up prospectively until the end of study. The interval of response evaluation is recommended to be every 2 to 3 months in the treatment period and the interval of follow-up is recommended to be every 2 to 3 months in the post-treatment period till the end of study in the prospective data collection period.

Eligibility Criteria:
Inclusion Criteria:

* A confirmed diagnosis of locally advanced or metastatic NSCLC.
* The tumor harbored common EGFR mutations (Del19, L858R) at start of first-line treatment
* Age ≥ 18 years
* Had never received any EGFR TKI therapy.
* Patients that treated with dacomitinib (Vizimpro®) as first-line treatment
* Confirmation of the T790M variant after first line dacomitinib treatment and receive any 3rd generation EGFR-TKI as second-line treatment.
* Asymptomatic CNS metastases allowed
* At least one lesion that can be accurately measured at baseline according to the RECIST 1.1, and which is suitable for accurate repeated measurements.
* Start second-line treatment with third generation EGFR TKI no later than 01 JAN2023（\>10 month before data cutoff date）
* All eligible patients are required to sign an informed consent before initiating the study

Exclusion Criteria:

* Patients who received drug(s) other than 3rd generation EGFR-TKI as the second-line treatment and/or patients who received drug(s) other than Dacomitinib (Vizimpro®) as the first-line treatment
* Received or currently receiving dacomitinib from any interventional clinical trial
Dysphagia Awareness In Medical and Nursing Students

A survey consisting of questions about swallowing and dysphagia was provided to universities' medicine and nursing students. The answers of students were analyzed

The undergraduate training of health care professionals may provide the necessary theoretical and practical approach to future nurses and physicians. This study was planned to investigate students' dysphagia knowledge level and awareness in the medicine and nursing faculties. A survey consisting of questions about swallowing and dysphagia was provided to universities' medicine and nursing students. The answers of students were analyzed

Eligibility Criteria:
Inclusion Criteria:

* The fourth, fifth, and sixth-grade students in the faculty of medicine
* The second, third, and fourth-grade students in the nursing faculty

Exclusion Criteria:

* The first, second and third-grade students in the faculty of medicine
* The first grade students in the nursing faculty